1807631-83-9
1807631-83-9
Chemical Structure
CJJ300
- CAS No.: 1807631-83-9
- Formula:C30H33N3
- Molecular Weight:435.60
IUPAC Name: N,N',N''-((2,4,6-trimethylbenzene-1,3,5-triyl)tris(methylene))trianiline
InChIKey: AKBFUAPLAQSPMJ-UHFFFAOYSA-N
SMILES: CC1=C(C(C)=C(C(C)=C1CNC2=CC=CC=C2)CNC3=CC=CC=C3)CNC4=CC=CC=C4
Biological Activity: CJJ300 is a transforming growth factor-β (TGF-β) inhibitor with an IC50 of 5.3 µM. CJJ300 inhibits TGF-β signaling by disrupting the formation of the TGF-β-TβR-I-TβR-II signaling complex[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CJJ300 | 99.36% | CJJ300 is a transforming growth factor-β (TGF-β) inhibitor with an IC50 of 5.3 µM. CJJ300 inhibits TGF-β signaling by disrupting the formation of the TGF-β-TβR-I-TβR-II signaling complex. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AMN082 free base | 98.37% | AMN082 free base, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 free base potently inhibits cAMP accumulation and stimulates GTPγS binding (EC50 values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 free base shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AMN082 (Standard) | ≥98% | AMN082 (Standard) is the analytical standard of AMN082. This product is intended for research and analytical applications. AMN082, a selective, orally active, and brain penetrant mGluR7 agonist, directly activates receptor signaling via an allosteric site in the transmembrane domain. AMN082 potently inhibits cAMP accumulation and stimulates GTPγS binding (EC50 values, 64-290 nM) at transfected mammalian cells expressing mGluR7. AMN082 shows selectivity over other mGluR subtypes and selected ionotropic glutamate receptors. Antidepressant effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sirtuin-1 inhibitor 1 | 98.09% | Sirtuin-1 inhibitor 1 (Compound 8) is an inhibitor of Sirtuin-1 that plays important roles in obesity-induced diabetes and aging-related diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DPPD | 98.02% | DPPD (N,N′-Diphenyl-p-phenylenediamine) is an orally active antioxidant. DPPD also acts as a toxic substance and pregnancy disruptor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Triphenylamine | 99.68% | Triphenylamine (N,N-Diphenylbenzenamine) is a highly fluorescent compound. Triphenylamine can induce apoptosis. Triphenylamine can be used as a fluorescent dye and is also used in photodynamic therapy research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
1,2-Dianilinoethane | 98.71% | 1,2-Dianilinoethane (N,N'-Diphenylethylenediamine) is a biochemical reagent that can be used as a biological material or organic compound for life science related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Benzylaniline | 99.88% | N-Benzylaniline (N-Phenylbenzylamine) is an N-alkylated derivative of aniline. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(4-(1,2,2-Triphenylvinyl)phenyl)methanamine | (4-(1,2,2-Triphenylvinyl)phenyl)methanamine (4-(1,2,2-Triphenylethenyl)phenyl]methanamine) is a metal-organic framework (MOF). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N1-Benzyl-N2-phenylethane-1,2-diamine hydrochloride | N1-Benzyl-N2-phenylethane-1,2-diamine hydrochloride is a pharmaceutical intermediate that can be used for the synthesis of α1a-adrenergic receptor antagonists. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Phenyl-N'-(2-methylphenyl)-p-phenylenediamine | N-Phenyl-N'-(2-methylphenyl)-p-phenylenediamine is a metal-organic framework (MOF). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
